Skip to main content

Inhibitor Therapeutics, Inc. (INTI)

OTCMKTS: INTI · Delayed Price · USD
0.1221 0.0001 (0.08%)
Sep 16, 2021 12:17 PM EDT - Market closed

Company Description

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States.

It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.

The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.

Inhibitor Therapeutics, Inc.
Inhibitor Therapeutics Logo
CountryUnited States
Founded1992
IndustryBiotechnology
SectorHealthcare
Employees1
CEONicholas Virca

Contact Details

Address:
4830 W. Kennedy Blvd.
Tampa, Florida 33609
United States
Phone888 841 6811
Websitehedgepathpharma.com

Stock Details

Ticker SymbolINTI
ExchangeOTCMKTS
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code1042418
CUSIP Number202739108
ISIN NumberUS45720M1053

Key Executives

NamePosition
Nicholas Jon VircaPresident and Chief Executive Officer
Garrison J. Hasara CPA, CPAChief Financial Officer, Treasurer, Corporate Secretary and Chief Compliance Officer